Ontamalimab
SHP647-301
Phase 3 small_molecule terminated
Quick answer
Ontamalimab for Ulcerative Colitis is a Phase 3 program (small_molecule) at Takeda Pharmaceuticals International AG with 3 ClinicalTrials.gov record(s).
Program details
- Company
- Takeda Pharmaceuticals International AG
- Indication
- Ulcerative Colitis
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- terminated